X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (86) 86
hematology (83) 83
middle aged (66) 66
female (64) 64
male (63) 63
adult (55) 55
aged (54) 54
index medicus (54) 54
oncology (45) 45
adolescent (25) 25
therapy (23) 23
transplantation (23) 23
treatment outcome (21) 21
aged, 80 and over (19) 19
flow cytometry (19) 19
prognosis (19) 19
stem cells (18) 18
survival (17) 17
immunophenotyping (15) 15
care and treatment (14) 14
chemotherapy (14) 14
disease-free survival (14) 14
survival analysis (13) 13
young adult (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
rituximab (12) 12
follow-up studies (11) 11
retrospective studies (11) 11
analysis (10) 10
cancer (10) 10
expression (10) 10
medicine & public health (10) 10
multiple myeloma (10) 10
risk factors (10) 10
chronic lymphocytic leukemia (9) 9
further section (9) 9
hematology, oncology and palliative medicine (9) 9
lymphomas (9) 9
minimal residual disease (9) 9
relapse (9) 9
remission induction (9) 9
medical research (8) 8
acute myeloid leukemia (7) 7
child (7) 7
dexamethasone (7) 7
diagnosis (7) 7
immunology (7) 7
medicine, experimental (7) 7
multiple myeloma - mortality (7) 7
remission (7) 7
salvage therapy (7) 7
survival rate (7) 7
acute lymphoblastic leukemia (6) 6
antibodies, monoclonal - therapeutic use (6) 6
antibodies, monoclonal, murine-derived (6) 6
antineoplastic agents - therapeutic use (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
bortezomib (6) 6
clinical trials (6) 6
efficacy (6) 6
kaplan-meier estimate (6) 6
lenalidomide (6) 6
leukemia (6) 6
management (6) 6
mortality (6) 6
multiple myeloma - drug therapy (6) 6
multivariate analysis (6) 6
neoplasm staging (6) 6
patient outcomes (6) 6
patients (6) 6
prospective studies (6) 6
recurrence (6) 6
stem cell transplantation (6) 6
antineoplastic agents - adverse effects (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
bone-marrow-transplantation (5) 5
brentuximab vedotin (5) 5
classification (5) 5
cohort studies (5) 5
disease (5) 5
double-blind (5) 5
drug therapy (5) 5
hematopoietic stem cell transplantation (5) 5
hematopoietic stem cells - immunology (5) 5
impact (5) 5
italy (5) 5
leukemia, lymphocytic, chronic, b-cell - drug therapy (5) 5
leukemia, lymphocytic, chronic, b-cell - immunology (5) 5
leukemia, lymphocytic, chronic, b-cell - mortality (5) 5
lymphoma (5) 5
melphalan - administration & dosage (5) 5
multiple-myeloma (5) 5
pharmacology & pharmacy (5) 5
precursor cell lymphoblastic leukemia-lymphoma - diagnosis (5) 5
precursor cell lymphoblastic leukemia-lymphoma - mortality (5) 5
prednisone - administration & dosage (5) 5
purpura (5) 5
thalidomide - administration & dosage (5) 5
thrombocytopenia (5) 5
trial (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 19, pp. 1759 - 1769
Journal Article
British Journal of Haematology, ISSN 0007-1048, 01/2016, Volume 172, Issue 1, pp. 111 - 121
Summary High‐dose chemotherapy (HDT) with autologous stem cell transplantation is the standard of care for relapsed/refractory (RR) Hodgkin lymphoma (HL).... 
high‐dose chemotherapy | fotemustine | autologous stem cell transplantation | Hodgkin lymphoma | High-dose chemotherapy | Autologous stem cell transplantation | Fotemustine | FDG-PET | fote-mustine | PULMONARY TOXICITY | PROGNOSTIC-FACTORS | BONE-MARROW-TRANSPLANTATION | STEM-CELL-TRANSPLANTATION | BRENTUXIMAB VEDOTIN | PREPARATIVE REGIMENS | RANDOMIZED-TRIAL | CONDITIONING REGIMEN | SALVAGE THERAPY | HEMATOLOGY | high-dose chemotherapy | Drug Evaluation - methods | Hodgkin Disease - diagnostic imaging | Nitrosourea Compounds - administration & dosage | Nitrosourea Compounds - adverse effects | Salvage Therapy - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Positron-Emission Tomography | Cytarabine - adverse effects | Young Adult | Melphalan - adverse effects | Hodgkin Disease - drug therapy | Adult | Female | Registries | Transplantation Conditioning - methods | Child | Organophosphorus Compounds - adverse effects | Etoposide - adverse effects | Kaplan-Meier Estimate | Etoposide - administration & dosage | Graft Survival | Treatment Outcome | Cytarabine - administration & dosage | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Aged | Organophosphorus Compounds - administration & dosage | Hematopoietic Stem Cell Transplantation - methods | Salvage Therapy - methods | Chemotherapy | Lymphomas | Patient outcomes | Stem cells | Cancer | Index Medicus | Research Paper | Haematological Malignancy
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 1, pp. 22 - 33
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2793 - 2793
Abstract Background.Acute myeloid leukemia (AML) is a heterogeneous disease with respect to cell phenotypes and clinical outcomes.Recently, detailed genetic... 
Journal Article
Annals of Hematology, ISSN 0939-5555, 1/2016, Volume 95, Issue 2, pp. 239 - 244
Immune thrombocytopenia (ITP) is a disease which sees one-third of patients failing first and subsequent therapeutic approaches, including splenectomy.... 
Splenectomy | Oncology | Thrombopoietin receptor agonists | Medicine & Public Health | Hematology | Immune thrombocytopenia (ITP)
Journal Article
Journal Article
Clinical Lymphoma Myeloma and Leukemia, ISSN 2152-2650, 09/2017, Volume 17, pp. S312 - S312
Journal Article
Clinical Lymphoma, Myeloma & Leukemia, ISSN 2152-2650, 09/2017, Volume 17, p. S312
Journal Article
Journal Article
The Lancet Oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated... 
CLINICAL-PRACTICE GUIDELINES | SURVIVAL | SUPPORT | IMPACT | CONSOLIDATION | RESPONSE CRITERIA | ONCOLOGY | R-CHOP | NON-HODGKIN-LYMPHOMA | ELDERLY-PATIENTS | MEGACHOEP | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells
Journal Article